Do we need individualised prescribing quality assessment? The case of diabetes treatment.
Prescribing quality assessment is increasingly used in improvement programs and pay-for-performance policies. Within the area of diabetes many quality indicators have been developed. Some measure prescribing on a general level, e.g. calculating percentages of patients prescribed any statins. Others...
| Publicado en: | International Journal of Clinical Pharmacy Vol. 33; no. 2; pp. 145 - 150 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Apr2011
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104573478&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104573478 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 22107703 BGX3 jtl: International Journal of Clinical Pharmacy issn: 22107703 maglogo: N pubinfo: dt: Apr2011 vid: 33 iid: 2 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 104573478 NLM21744186 2011210874 10.1007/s11096-010-9471-0 NLM21744186 104573478 ppf: 145 ppct: 5 formats: tig: atl: Do we need individualised prescribing quality assessment? The case of diabetes treatment. aug: au: Denig P Haaijer-Ruskamp F Denig, Petra Haaijer-Ruskamp, Flora affil: Department of Clinical Pharmacology, University of Groningen, Groningen, The Netherland sug: subj: Diabetes Mellitus, Type 2 Drug Therapy Hypoglycemic Agents Therapeutic Use Pharmacy Service Standards Quality Assurance Standards Quality Improvement Standards Clinical Indicators Standards Prescriptions, Drug Standards Treatment Outcomes ab: Prescribing quality assessment is increasingly used in improvement programs and pay-for-performance policies. Within the area of diabetes many quality indicators have been developed. Some measure prescribing on a general level, e.g. calculating percentages of patients prescribed any statins. Others are very specific, e.g. percentages of patients with an elevated LDL-cholesterol in whom lipid-lowering treatment is started unless contraindicated or return to control within 3 months. Although the latter seems more precise, we question how far one should go in developing such indicators. Using the example of diabetes treatment, we highlight the need, opportunities, and feasibility of assessing prescribing quality in the context of individualised treatment. We conclude that it is not realistic to develop indicators that take all possible aspects of therapy non-response, intolerance and patient preferences into account. We do recommend further development of indicators that better address subpopulations in need of adjusted treatment, such as elderly or patients with comorbidity. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|